PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Razoxane”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1978

Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.

Comparison of the recurrence rates of soft tissue sarcomas treated by radiotherapy (14 patients) or radiotherapy and synchronous administration of razoxane (19 patients) has shown a statistically significant benefit for those patients treated by the combination. No increase in tissue reactions or adverse side-effects (apart from a readily reversible leukopenia) was observed. The implication is that razoxane acts as a well tolerated adjuvant for radiotherapy.

Adult↗
PubMed1979

Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.

Eight patients with 12 chondrosarcomas were treated with radiation and razoxane (ICRF 159). Two tumors in 1 patient progressed unequivocally, 3 tumors in 3 patients showed no change, and 7 tumors in 5 patients had complete or partial (more than 50%) regressions. At least 2 complete regressions have responded for more than 2 1/2 years at the present time.

Adult↗
PubMedDate not supplied

Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane).

Eleven patients with myeloid blast cell crisis and two patients with lymphoid blast cell crisis of chronic myeloid leukemia were treated with ICRF-159. Two of the patients with myeloid blast cell crisis achieved partial bone marrow remission and survived for 8+ and 18 months. One of the patients with lymphoid blast cell crisis reverted to the chronic phase of chronic myeloid leukemia after therapy with ICRF-159 in combination with prednisolone. The only significant toxic effect was myelosuppression.

Adolescent↗
PubMed1979

ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.

ICRF-159 is active in several animal tumor model systems and human adult malignancies. In this phase II study, ICRF-159 was given on a weekly schedule, 3000 mg/m2/day, orally in three divided doses at 6-hour intervals to 78 children with a variety of malignant neoplasms. Fifty-three patients were evaluable for tumor response. Toxicity was primarily hematopoietic and gastrointestinal. There were no responses in any of the eight patients with osteogenic sarcoma, four with lymphoma, five with Ewing's sarcoma, ten with neuroblastoma, or six with rhabdomyosarcoma. There was a transient partial response in one of four children with Wilms' tumor. Further trials with this drug using this schedule are not indicated for the common childhood solid tumors.

Adolescent↗
PubMed1978

Inhibition of collagen peptidase in HeLa cells and human tumours by compounds including drugs used in cancer therapy.

Collagen-peptidase activity in extracts of HeLa cells and human tumours is inactivated by Razoxane (ICRF-159), cyclophosphamide, 5-fluorouracil, thiotepa, aprotinin, EDTA and phenanthroline. As this activity, in association with other enzymes, may contribute to tissue lysis in cancers, chemical intervention may reduce invasiveness and modify the processes of infiltration and metastasis. Accordingly, some drugs used in therapy or for the prevention of metastasis may produce their observed effects by a combination of factors including enzyme inhibition.

Antineoplastic Agents↗